{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:04:26Z","timestamp":1793160266983,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["ROI CA203883 (Rahbar )"],"award-info":[{"award-number":["ROI CA203883 (Rahbar )"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1245\/s10434-024-16837-x","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:05:43Z","timestamp":1738080343000},"page":"3234-3243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preoperative MRI to Predict Upstaging of DCIS to Invasive Cancer at Surgery"],"prefix":"10.1245","volume":"32","author":[{"given":"Sara H.","family":"Javid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum S.","family":"Kazerouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Schnuck-Olapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debosmita","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dontchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kilgore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah C.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"16837_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CACancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CACancer J Clin"},{"key":"16837_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/jnci\/djp482","volume":"102","author":"BA Virnig","year":"2010","unstructured":"Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170\u20138. https:\/\/doi.org\/10.1093\/jnci\/djp482.","journal-title":"J Natl Cancer Inst"},{"key":"16837_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97:135\u201344. https:\/\/doi.org\/10.1007\/s10549-005-9101-z.","journal-title":"Breast Cancer Res Treat"},{"key":"16837_CR4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y","volume":"49","author":"DL Page","year":"1982","unstructured":"Page DL, Dupont WD, Rogers LW. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49:751\u20138.","journal-title":"Cancer"},{"key":"16837_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, et al. NCCN guidelines(R) insights: breast cancer, version 4.2023. J Natl Compr Canc Netw. 2023;21:594\u2013608. https:\/\/doi.org\/10.6004\/jnccn.2023.0031.","journal-title":"J Natl Compr Canc Netw"},{"key":"16837_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.11102368","volume":"260","author":"ME Brennan","year":"2011","unstructured":"Brennan ME, et al. Ductal carcinoma in situ at core needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260:119\u201328.","journal-title":"Radiology"},{"key":"16837_CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.crad.2014.12.019","volume":"70","author":"YT Sim","year":"2015","unstructured":"Sim YT, et al. Upgrade of ductal carcinoma in situ on core biopsies to invasive disease at final surgery: a retrospective review across the Scotish Breast Screening Programme. Clin Radiol. 2015;70:502\u20136.","journal-title":"Clin Radiol"},{"key":"16837_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","volume":"105","author":"LJ Solin","year":"2013","unstructured":"Solin LJ, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. JNCI J Natl Cancer Inst. 2013;105:701\u201310. https:\/\/doi.org\/10.1093\/jnci\/djt067.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"16837_CR9","doi-asserted-by":"publisher","first-page":"100607","DOI":"10.1016\/j.adro.2020.10.020","volume":"6","author":"RY Lei","year":"2021","unstructured":"Lei RY, et al. A comparison of predicted ipsilateral tumor recurrence risks in patients with ductal carcinoma in situ of the breast after breast-conserving surgery by breast radiation oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS nomogram, and the 12-gene DCIS score assay. Adv Radiat Oncol. 2021;6:100607. https:\/\/doi.org\/10.1016\/j.adro.2020.10.020.","journal-title":"Adv Radiat Oncol"},{"key":"16837_CR10","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","volume":"28","author":"C Shah","year":"2021","unstructured":"Shah C, et al. The clinical utility of DCISionRT((R)) on radiation therapy decision-making in patients with ductal carcinoma in situ following breast-conserving surgery. Ann Surg Oncol. 2021;28:5974\u201384. https:\/\/doi.org\/10.1245\/s10434-021-09903-1.","journal-title":"Ann Surg Oncol"},{"key":"16837_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(07)61232-X","volume":"370","author":"CK Kuhl","year":"2007","unstructured":"Kuhl CK, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007;370:485\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(07)61232-X.","journal-title":"Lancet"},{"key":"16837_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1148\/radiol.2017161449","volume":"284","author":"CK Kuhl","year":"2017","unstructured":"Kuhl CK, et al. Impact of preoperative breast MR imaging and MR-guided surgery on diagnosis and surgical outcome of women with invasive breast cancer with and without DCIS component. Radiology. 2017;284:645\u201355. https:\/\/doi.org\/10.1148\/radiol.2017161449.","journal-title":"Radiology"},{"key":"16837_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1148\/radiol.12111368","volume":"263","author":"H Rahbar","year":"2012","unstructured":"Rahbar H, et al. In vivo assessment of ductal carcinoma in situ grade: a model incorporating dynamic contrast-enhanced and diffusion-weighted breast MR imaging parameters. Radiology. 2012;263:374\u201382. https:\/\/doi.org\/10.1148\/radiol.12111368.","journal-title":"Radiology"},{"key":"16837_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.clinimag.2015.07.026","volume":"40","author":"H Rahbar","year":"2016","unstructured":"Rahbar H, et al. Can MRI biomarkers at 3T identify low-risk ductal carcinoma in situ? Clin Imaging. 2016;40:125\u20139. https:\/\/doi.org\/10.1016\/j.clinimag.2015.07.026.","journal-title":"Clin Imaging"},{"key":"16837_CR15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s00330-019-06510-3","volume":"30","author":"P Baltzer","year":"2020","unstructured":"Baltzer P, et al. Diffusion-weighted imaging of the breast: a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group. Eur Radiol. 2020;30:1436\u201350. https:\/\/doi.org\/10.1007\/s00330-019-06510-3.","journal-title":"Eur Radiol"},{"key":"16837_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"2018","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 2018;57:289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"16837_CR17","doi-asserted-by":"publisher","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, et al. The COMET (Comparison of Operative vs Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797. https:\/\/doi.org\/10.1136\/bmjopen-2018-026797.","journal-title":"BMJ Open"},{"key":"16837_CR18","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51:2296\u2013303. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.017.","journal-title":"Eur J Cancer"},{"key":"16837_CR19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ: the LORD study. Eur J Cancer. 2015;51:1497\u2013510. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.008.","journal-title":"Eur J Cancer"},{"key":"16837_CR20","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1245\/s10434-020-08637-w","volume":"27","author":"TO Oseni","year":"2020","unstructured":"Oseni TO, Bahl M. ASO Author reflections: active surveillance for ductal carcinoma in situ (DCIS). Ann Surg Oncol. 2020;27:4466\u20137.","journal-title":"Ann Surg Oncol"},{"key":"16837_CR21","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, et al. Surgical upstaging rates for vacuum-assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol. 2017;24:3534\u201340. https:\/\/doi.org\/10.1245\/s10434-017-6018-9.","journal-title":"Ann Surg Oncol"},{"key":"16837_CR22","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1245\/s10434-016-5595-3","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Olcese C, Patil S, Van Zee KJ. Women with low-risk DCIS eligible for the LORIS trial after complete surgical excision: How low is their risk after standard therapy? Ann Surg Oncol. 2016;23:4253\u201361.","journal-title":"Ann Surg Oncol"},{"key":"16837_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2214\/AJR.20.23679","volume":"216","author":"LJ Grimm","year":"2021","unstructured":"Grimm LJ, et al. Mixed-methods study to predict upstaging of DCIS to invasive disease on mammography. AJR Am J Roentgenol. 2021;216:903\u201311. https:\/\/doi.org\/10.2214\/AJR.20.23679.","journal-title":"AJR Am J Roentgenol"},{"key":"16837_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1148\/radiol.210407","volume":"303","author":"R Hou","year":"2022","unstructured":"Hou R, et al. Prediction of upstaging in ductal carcinoma in situ based on mammographic radiomic features. Radiology. 2022;303:54\u201362. https:\/\/doi.org\/10.1148\/radiol.210407.","journal-title":"Radiology"},{"key":"16837_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/tbj.12201","volume":"19","author":"DJ Wisner","year":"2013","unstructured":"Wisner DJ, et al. Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J. 2013;19:650\u20138. https:\/\/doi.org\/10.1111\/tbj.12201.","journal-title":"Breast J."},{"key":"16837_CR26","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.acra.2019.09.025","volume":"27","author":"LR Lamb","year":"2020","unstructured":"Lamb LR, Lehman CD, Oseni TO, Bahl M. Ductal carcinoma in situ (DCIS) at breast MRI: predictors of upgrade to invasive carcinoma. Acad Radiol. 2020;27:1394\u20139. https:\/\/doi.org\/10.1016\/j.acra.2019.09.025.","journal-title":"Acad Radiol"},{"key":"16837_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1148\/radiol.2021204743","volume":"301","author":"S-HS Chou","year":"2021","unstructured":"Chou S-HS, et al. Preoperative breast MRI for newly diagnosed ductal carcinoma in situ: imaging features and performance in a multicenter setting (ECOG-ACRIN E4112 trial). Radiology. 2021;301:66\u201377. https:\/\/doi.org\/10.1148\/radiol.2021204743.","journal-title":"Radiology"},{"key":"16837_CR28","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1245\/s10434-017-5927-y","volume":"24","author":"JW Jakub","year":"2017","unstructured":"Jakub JW, et al. A validated nomogram to predict upstaging of ductal carcinoma in situ to invasive disease. Ann Surg Oncol. 2017;24:2915\u201324. https:\/\/doi.org\/10.1245\/s10434-017-5927-y.","journal-title":"Ann Surg Oncol"},{"key":"16837_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4258\/hir.2014.20.2.152","volume":"20","author":"SC Lee","year":"2014","unstructured":"Lee SC, Chang MC. Development and validation of web-based nomograms to predict postoperative invasive component in ductal carcinoma in situ at needle breast biopsy. Healthc Inform Res. 2014;20:152\u20136. https:\/\/doi.org\/10.4258\/hir.2014.20.2.152.","journal-title":"Healthc Inform Res"},{"key":"16837_CR30","doi-asserted-by":"publisher","first-page":"7069","DOI":"10.1245\/s10434-023-13929-y","volume":"30","author":"CJC Meurs","year":"2023","unstructured":"Meurs CJC, et al. Validation and clinical utility of a prediction model for the risk of upstaging to invasive breast cancer after a biopsy diagnosis ductal carcinoma in situ. Ann Surg Oncol. 2023;30:7069\u201380. https:\/\/doi.org\/10.1245\/s10434-023-13929-y.","journal-title":"Ann Surg Oncol"},{"key":"16837_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2017.04.013","volume":"80","author":"T Onega","year":"2017","unstructured":"Onega T, et al. The diagnostic challenge of low-grade ductal carcinoma in situ. Eur J Cancer. 2017;80:39\u201347.","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1245\/s10434-025-17029-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16837-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T06:57:34Z","timestamp":1744095454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16837-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["16837"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16837-x","relation":{"correction":[{"id-type":"doi","id":"10.1245\/s10434-025-17029-x","asserted-by":"object"}]},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1245\/s10434-025-17029-x","URL":"https:\/\/doi.org\/10.1245\/s10434-025-17029-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Habib Rahbar participated as a co-investigator on a study not related to this work supported by GE Healthcare during the same time frame as this trial. He is the PI on a separate grant supported by Guerbet, LLC, on a study not related to this work. This study did not overlap with this trial. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}